Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Sorafenib is the standard therapy for advanced liver cancer but often shows dose-limiting
toxicities with the need to reduce the applied dose of the compound. As this limits the
overall response rate of the therapy, a combination with temsirolimus, an inhibitor of mTOR
signaling, will be investigated regarding safety and tolerability in patients with advanced
liver cancer under a reduced dose of sorafenib.